11:56 PM
Login form
Entries archive

My site

Main » 2022 » December » 14

SAN FRANCISCO - Wednesday, 14. December 2022

(BUSINESS WIRE) -- Andersen Global further advances its expansion efforts across Brazil and Europe through a Collaboration Agreement with Rolim, a comprehensive legal firm with offices in São Paulo, Rio de Janeiro, Belo Horizonte and Brasília.

Founded by Managing Partner João Dácio Rolim in 1993, the firm’s team of professionals provides services in areas including tax, energy, telecommunications, business litigation, arbitration and mediation, corporate law, mergers and acquisitions, environmental law, contracts, infrastructure, international trade and customs, real estate, and antitrust. Rolim is consistently recognized by Chambers and Partners, IFLR 1000, ITR World Tax, Leaders League and The Legal 500 as a top-performing law firm.

“Our team maintains deep knowledge of the current business landscape and remains committed to delivering quality, comprehensive solutions to our local and internati ... Read more »

Views: 52 | Added by: africa-live | Date: 12.14.2022 | Comments (0)

NOIDA, India & ZURICH - Tuesday, 13. December 2022

HCLTech’s automation and artificial intelligence solutions to enhance cybersecurity and employee experience at one of the world’s largest snack companies

(BUSINESS WIRE) -- HCL Technologies (HCLTech), a leading global technology company, announced an expanded multi-year contract with Mondelēz International, to enhance Mondelēz International’s cybersecurity and transform digital workplace services globally.

To support its hybrid workplace model, Mondelēz International deployed HCLTech’s top rated BigFix platform to automate the discovery and remediation of potential vulnerabilities, ensuring all endpoints – including servers, mobile devices and laptops, are continuously secured and compliant.

HCLTech will leverage its automation and artificial intelligence (AI) capabilities to enable Mondelēz International to provide an intuitive, on-demand personalized user experience ... Read more »

Views: 48 | Added by: africa-live | Date: 12.14.2022 | Comments (0)

LONDON - Tuesday, 13. December 2022

    Study shows Velo consumers had significantly better results for several indicators linked to smoking-related diseases compared with smokers
    Results provide important new data and insights into the real-world health impact that underscores the Tobacco Harm Reduction potential of oral nicotine pouches
    Study adds to the weight of evidence that supports Velo as a reduced-risk* product for smokers who completely switch from smoking   
    Results reinforce BAT’s ability to deliver A Better TomorrowTM by reducing the health impact of its business


(BUSINESS WIRE) -- New results from an innovative cross-sectional clinical study of Velo i, BAT’s flagship modern oral nicotine pouch product, have been published today in Biomarkers Journal. In the study, consumers exclusively using Velo for over six months had s ... Read more »

Views: 43 | Added by: africa-live | Date: 12.14.2022

GHENT, Belgium - Tuesday, 13. December 2022 AETOSWire Print 

(BUSINESS WIRE)--MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved preclinical development targets. With the achievement of this new milestone, both companies will now advance this research which focuses on developing innovative therapies for metabolic diseases to the clinical development stage.

IFF joined forces with microbiome specialist MRM Health in 2020, aiming to tackle a range of metabolic diseases. In this research, the proprietary MRM Health CORAL® technology platform and some selected IFF strains will be combined to develop novel therapeutics based on live bacterial strain combinations.

“We are very pleased to see the progress that MRM Health and IFF have made within our par ... Read more »

Views: 46 | Added by: africa-live | Date: 12.14.2022 | Comments (0)

VIENNA - Tuesday, 13. December 2022

(BUSINESS WIRE) -- AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Health´s CONTINUATION-PV study (Reference Kiladjian et al. ASH 2022) and the LOW-PV trial, which is an independent investigator-initiated trial supported by AOP Health ( ... Read more »

Views: 48 | Added by: africa-live | Date: 12.14.2022 | Comments (0)

Investors are encouraged to watch the Company’s new video, outlining Coretec’s Endurion technology and its unique approach to battery development.

(BUSINESS WIRE) -- The Coretec Group (OTCQB: CRTG), developers of silicon anode active materials in lithium-ion batteries for EV, cleantech, and emerging tech applications, today released a short, informative video for investors and the public to view, ahead of its upcoming shareholder call at 10:00 a.m. EST on Wednesday, December 14, 2022.

The video clip can be viewed below:

The shareholder call will cover Coretec’s accomplishments from 2022, provide updates to its Endurion battery program, and outline corporate plans for growth in the new year. Company leaders will also answer pre-submitted questions from the investment community, potential partners and news media.

Webcast Details

Audience Link

Where attendees will register and view th ... Read more »

Views: 47 | Added by: africa-live | Date: 12.14.2022 | Comments (0)

Dubai, United Arab Emirates - Tuesday, 13. December 2022

Shipsy, a leading SaaS-based smart logistics management provider, recently announced its first ESOP buyback. The buyback was open to all existing, full-time employees of Shipsy who have completed at least one year of full-time employment. Shipsy's early-stage investors have already realised the significant value in the organisation's secondary and buyback transactions in the past one and a half years.


Shipsy is clocking a growth rate of 2.5x YoY. It recorded its recurring revenue growth of over 100% and grew its customer base by 75% last year. To scale its operations, the SaaS provider is rapidly expanding its employee pool and hiring top talent from across the globe. In a span of fewer than seven years, Shipsy’s people strength has crossed more than 350. Also, to ensure rapid adoption of its technology across the globe, Shipsy is partnering with global system integrators, evangelis ... Read more »

Views: 41 | Added by: africa-live | Date: 12.14.2022 | Comments (0)

(BUSINESS WIRE)--Japan Tobacco Inc. (JT) (TSE: 2914) announces today that it has been included in the Dow Jones Sustainability Asia Pacific Index (“DJSI Asia Pacific”), for the ninth consecutive year, reflecting the company’s continued approach to addressing social and environmental issues across its value chain.

The DJSI is a globally recognized environmental, social and governance (ESG) stock index1 and sustainability benchmark that tracks the stock performance of the world's leading companies in terms of governance and economic, environmental and social dimensions, with constituents selected on the basis of the S&P Global Corporate Sustainability Assessment (CSA)2. The DJSI Asia Pacific is an index of companies in the Asia-Pacific region, which is reviewed once a year and whose constituents are selected from approximately 600 major companies in the region.

The DJSI applies a comprehensive approach which incorporates the ... Read more »

Views: 47 | Added by: africa-live | Date: 12.14.2022 | Comments (0)

• EC grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which demonstrated that over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose1,2

• Generalized pustular psoriasis (GPP) differs significantly from plaque psoriasis in both its disease mechanism and severity2,3,4

• The EMA’s decision builds on existing approvals in the USA and Japan5


(BUSINESS WIRE) -- The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for GPP flares in adults.1 Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP.2, 4-7


“The symptoms of GPP are devastating and cause immense pain as well as hospitalizat ... Read more »

Views: 45 | Added by: africa-live | Date: 12.14.2022 | Comments (0)